Research advances in the role of fecal calprotectin in intestinal development and diseases among children

LI Feng; SHENG Xiao-Yang

doi:10.7499/j.issn.1008-8830.2014.10.023

PDF(1499 KB)

Chinese Journal of Contemporary Pediatrics ›› 2014, Vol. 16 ›› Issue (10) : 1064-1069. DOI: 10.7499/j.issn.1008-8830.2014.10.023

REVIEW

Research advances in the role of fecal calprotectin in intestinal development and diseases among children

LI Feng, SHENG Xiao-Yang

Author information +

History +

Abstract

Calprotectin is a calcium- and zinc-binding protein of the S100 family expressed mainly by neutrophils with important extracellular activity. This paper reviews current findings concerning the relationship between faecal calprotectin and intestinal development among children, influencing factors of fecal calprotectin and the implication of faecal calprotectin in the diagnosis, follow-up, assessment of relapses, and response to treatment in pediatric intestinal diseases, such as necrotizing enterocolitis, inflammatory bowel disease, intestinal infection, celiac disease and allergy. Further studies are required to provide insights into the actual role of calprotectin in physiological and pathological processes in pediatrics.

Key words

Calprotectin / Intestinal disease / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Feng, SHENG Xiao-Yang. Research advances in the role of fecal calprotectin in intestinal development and diseases among children[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(10): 1064-1069 https://doi.org/10.7499/j.issn.1008-8830.2014.10.023

References

[1] Vaos G, Kostakis ID, Zavras N, et al. The role of calprotectin inpediatric disease[J]. Biomed Res Int, 2013, 2013: 542363.
[2] Roseth AG, Schmidt PN, Fagerhol MK. Correlation betweenfaecal excretion of indium-111-labelled granulocytes andcalprotectin, a granulocyte marker protein, in patients withinflammatory bowel disease[J]. Scand J Gastroenterol, 1999,34(1): 50-54.
[3] Fagerberg UL, Loof L, Merzoug RD, et al. Fecal calprotectinlevels in healthy children studied with an improved assay[J]. JPediatr Gastroenterol Nutr, 2003, 37(4): 468-472.
[4] Turkay C, Kasapoglu B. Noninvasive methods in evaluationof inflammatory bowel disease: where do we stand now? Anupdate[J]. Clinics (Sao Paulo), 2010, 65(2): 221-231.
[5] Ton H, Brandsnes, Dale S, et al. Improved assay for fecalcalprotectin[J]. Clin Chim Acta, 2000, 292(1-2): 41-54.
[6] Gisbert JP, McNicholl AG. Questions and answers on the role offaecal calprotectin as a biological marker in inflammatory boweldisease[J]. Dig Liver Dis, 2009, 41(1): 56-66.
[7] Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammationis well predicted by fecal calprotectin in children withgastrointestinal symptoms[J]. J Pediatr Gastroenterol Nutr,2005, 40(4): 450-455.
[8] Kapel N, Campeotto F, Kalach N, et al. Faecal calprotectin interm and preterm neonates[J]. J Pediatr Gastroenterol Nutr,2010, 51(5): 542-547.
[9] Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levelsin infants with infantile colic, healthy infants, children withinflammatory bowel disease, children with recurrent abdominalpain and healthy children[J]. Acta Paediatr, 2002, 91(1): 45-50.
[10] Savino F, Castagno E, Calabrese R, et al. High faecalcalprotectin levels in healthy, exclusively breast-fed infants[J].Neonatology, 2010, 97(4): 299-304.
[11] Rouge C, Butel MJ, Piloquet H, et al. Fecal calprotectinexcretion in preterm infants during the neonatal period[J]. PLoSOne, 2010, 5(6): e11083.
[12] Sykora J, Siala K, Huml M, et al. Evaluation of faecalcalprotectin as a valuable non-invasive marker in distinguishinggut pathogens in young children with acute gastroenteritis[J].Acta Paediatr, 2010, 99(9): 1389-1395.
[13] Zoppelli L, Guttel C, Bittrich HJ, et al. Fecal calprotectinconcentrations in premature infants have a lower limit and showpostnatal and gestational age dependence[J]. Neonatology,2012, 102(1): 68-74.
[14] Laforgia N, Baldassarre ME, Pontrelli G, et al. Calprotectinlevels in meconium[J]. Acta Paediatr, 2003, 92(4): 463-466.
[15] Josefsson S, Bunn SK, Domellof M. Fecal calprotectin in verylow birth weight infants[J]. J Pediatr Gastroenterol Nutr, 2007,44(4): 407-413.
[16] Nissen AC, van Gils CE, Menheere PP, et al. Fecal calprotectinin healthy term and preterm infants[J]. J Pediatr GastroenterolNutr, 2004, 38(1): 107-108.
[17] Campeotto F, Butel MJ, Kalach N, et al. High faecal calprotectinconcentrations in newborn infants[J]. Arch Dis Child FetalNeonatal Ed, 2004, 89(4): F353-355.
[18] Baldassarre ME, Altomare MA, Fanelli M, et al. Doescalprotectin represent a regulatory factor in host defense or adrug target in inflammatory disease?[J]. Endocr Metab ImmuneDisord Drug Targets, 2007, 7(1): 1-5.
[19] Rhoads JM, Fatheree NY, Norori J, et al. Altered fecalmicroflora and increased fecal calprotectin in infants withcolic[J]. J Pediatr, 2009, 155(6): 823-828.
[20] Rosti L, Braga M, Fulcieri C, et al. Formula milk feeding doesnot increase the release of the inflammatory marker calprotectin,compared to human milk[J]. Pediatr Med Chir, 2011, 33(4):178-181.
[21] Dorosko SM, Mackenzie T, Connor RI. Fecal calprotectinconcentrations are higher in exclusively breastfed infantscompared to those who are mixed-fed[J]. Breastfeed Med, 2008,3(2): 117-119.
[22] Hestvik E, Tumwine JK, Tylleskar T, et al. Faecal calprotectinconcentrations in apparently healthy children aged 0-12 years inurban Kampala, Uganda: a community-based survey[J]. BMCPediatr, 2011, 11: 9.
[23] Baldassarre ME, Laforgia N, Fanelli M, et al. LactobacillusGG improves recovery in infants with blood in the stoolsand presumptive allergic colitis compared with extensivelyhydrolyzed formula alone[J]. J Pediatr, 2010, 156(3): 397-401.
[24] 张杰, 刘金荣, 盛晓阳, 等. 6~18 月龄婴幼儿粪钙卫蛋白水平及其变化趋势[J]. 肠外与肠内营养, 2012, 19(4): 214-217.
[25] Taylor SN, Basile LA, Ebeling M, et al. Intestinal permeabilityin preterm infants by feeding type: mother's milk versusformula[J]. Breastfeed Med, 2009, 4(1): 11-15.
[26] Campeotto F, Kalach N, Lapillonne A, et al. Time course offaecal calprotectin in preterm newborns during the first month oflife[J]. Acta Paediatr, 2007, 96(10): 1531-1533.
[27] Campeotto F, Baldassarre M, Butel MJ, et al. Fecal calprotectin:cutoff values for identifying intestinal distress in preterminfants[J]. J Pediatr Gastroenterol Nutr, 2009, 48(4): 507-510.
[28] Carroll D, Corfield A, Spicer R, et al. Faecal calprotectinconcentrations and diagnosis of necrotising enterocolitis[J].Lancet, 2003, 361(9354): 310-311.
[29] Yang Q, Smith PB, Goldberg RN, et al. Dynamic change offecal calprotectin in very low birth weight infants during the firstmonth of life[J]. Neonatology, 2008, 94(4): 267-271.
[30] Westerbeek EA, Morch E, Lafeber HN, et al. Effect of neutraland acidic oligosaccharides on fecal IL-8 and fecal calprotectinin preterm infants[J]. Pediatr Res, 2011, 69(3): 255-258.
[31] Mohan R, Koebnick C, Schildt J , e t al. Effects ofBifidobacterium lactis Bb12 supplementation on body weight,fecal pH, acetate, lactate, calprotectin, and IgA in preterminfants[J]. Pediatr Res, 2008, 64(4): 418-422.
[32] Baldassarre ME, Fanelli M, Lasorella ML, et al. Fecalcalprotectin (FC) in newborns: is it a predictive marker ofgastrointestinal and/or allergic disease?[J]. ImmunopharmacolImmunotoxicol, 2011, 33(1): 220-223.
[33] Aydemir O, Aydemir C, Sarikabadayi YU, et al. Fecal calprotectin levels are increased in infants with necrotizingenterocolitis[J]. J Matern Fetal Neonatal Med, 2012, 25(11):2237-2241.
[34] Thuijls G, Derikx JP, van Wijck K, et al. Non-invasive markersfor early diagnosis and determination of the severity ofnecrotizing enterocolitis[J]. Ann Surg, 2010, 251(6): 1174-1180.
[35] Reisinger KW, Van der Zee DC, Brouwers HA, et al.Noninvasive measurement of fecal calprotectin and serumamyloid A combined with intestinal fatty acid-binding protein innecrotizing enterocolitis[J]. J Pediatr Surg, 2012, 47(9): 1640-1645.
[36] Selimoglu MA, Temel I, Yildirim C, et al. The role of fecalcalprotectin and lactoferrin in the diagnosis of necrotizingenterocolitis[J]. Pediatr Crit Care Med, 2012, 13(4): 452-454.
[37] Kallel L, Fekih M, Boubaker J, et al. Faecal calprotectin ininflammatory bowel diseases: review[J]. Tunis Med, 2011,89(5): 425-429.
[38] Kostakis ID, Cholidou KG, Vaiopoulos AG, et al. Fecalcalprotectin in pediatric inflammatory bowel disease: asystematic review[J]. Dig Dis Sci, 2013, 58(2): 309-319.
[39] Waugh N, Cummins E, Royle P, et al. Faecal calprotectin testingfor differentiating amongst inflammatory and non-inflammatorybowel diseases: systematic review and economic evaluation[J].Health Technol Assess, 2013, 17(55): 1-212.
[40] Chen CC, Huang JL, Chang CJ, et al. Fecal calprotectin as acorrelative marker in clinical severity of infectious diarrheaand usefulness in evaluating bacterial or viral pathogens inchildren[J]. J Pediatr Gastroenterol Nutr, 2012, 55(5): 541-547.
[41] Kapel N, Roman C, Caldari D, et al. Fecal tumor necrosisfactor-alpha and calprotectin as differential diagnostic markersfor severe diarrhea of small infants[J]. J Pediatr GastroenterolNutr, 2005, 41(4): 396-400.
[42] Balamtekin N, Baysoy G, Uslu N, et al. Fecal calprotectinconcentration is increased in children with celiac disease:relation with histopathological findings[J]. Turk J Gastroenterol,2012, 23(5): 503-508.
[43] Ertekin V, Selimoglu MA, Turgut A, et al. Fecal calprotectinconcentration in celiac disease[J]. J Clin Gastroenterol, 2010,44(8): 544-546.
[44] Waligora-Dupriet AJ, Campeotto F, Romero K, et al. Diversityof gut Bifidobacterium species is not altered between allergicand non-allergic French infants[J]. Anaerobe, 2011, 17(3): 91-96.
[45] Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnosticvalue of faecal calprotectin in paediatric gastroenterologyclinical practice[J]. Dig Liver Dis, 2004, 36(7): 467-470.